Welcome to the Cannabis Investing Newsletter Forum. This is for the cannabis stocks forum & discussion. Feel free to find your favorite cannabis stocks and contribute content as you please; content that continues the discussion of, and analysis of, cannabis stocks. – D. H. Taylor
Halo Announces Results of Annual General and Special Meeting
|
Name of Nominee |
Votes cast FOR |
% votes cast FOR |
Votes |
% votes |
|
Kiran Sidhu |
7,246,248 |
97.96 % |
150,751 |
2.04 % |
|
Katharyn Field |
7,301,999 |
98.72 % |
95,000 |
1.28 % |
|
Dhaliwal |
7,303,802 |
98.78 % |
90,415 |
1.22 % |
|
Quinn Field-Dyte |
7,300,483 |
98.70 % |
96,516 |
1.30 % |
|
Anmol Sidhu |
7,284,407 |
98.52 % |
109,722 |
1.48 % |
|
Ryan Kunkel |
7,329,072 |
99.08 % |
67,927 |
0.92 % |
At the Meeting the shareholders of the Company also approved:
- the re-appointment of Davidson & Company LLP as the Company's auditors for the ensuing year and authorized the board of directors to fix the auditors' remuneration;
- one or more amendments to the articles of the Company for one or more future consolidations of the Company's issued and outstanding common shares on the basis of consolidation ratios to be selected by the board of directors of the Company within a range between 10 pre-consolidation common shares for one (1) post-consolidation common share and 100 pre-consolidation common shares for one (1) post-consolidation common share, provided that, (a) the cumulative effect of the one or more consolidations shall not result in a consolidation ratio that exceeds 100 pre-consolidation common shares for one (1) post-consolidation common share, and (B) such consolidations occur prior to the earlier of the 12 month anniversary of the Meeting and the next annual meeting of shareholders; if, and at such time(s) following the date of the Meeting, as may be determined by the board of directors of the Company in its sole discretion; and
- a special resolution was passed authorizing the Company to reduce the stated capital of its common shares;
each as more particularly described in the Information Circular.
The Company has filed a report of the voting results on all resolutions voted on at the Meeting on the Company's SEDAR profile at www.sedar.com.
About Halo Collective Inc.
Halo is a multi-national, incubation company with assets and operations centered in both THC and non-THC sectors. For the THC sector, Halo is focused on the West Coast of the United States where it has vertically integrated operations covering the entire value chain from seed to sale. Halo cultivates, extracts, manufactures, and distributes quality cannabis flower, pre-rolls, vape carts, edibles, and concentrates. Halo sells these products under a portfolio of brands including Hush™, Winberry Farms™, Williams Wonder Farms, its retail brand Budega™, and under license agreements with Papa's Herb®, DNA Genetics, and FlowerShop*. Halo has opened a dispensary in Los Angeles under the Budega™ brand in North Hollywood and plans to open two more in Hollywood, and Westwood in the second quarter of 2022. Halo also operates three Kushbar retail cannabis stores located in Alberta, Canada.
In the non-THC sector, Halo is expanding into health and wellness categories including CBD and functional supplements such as nootropic nutraceuticals and non-psychotropic mushrooms. Halo, through a series of acquisitions, has product offerings in the form of beverages (H2C Beverages), dissolvable strips (Dissolve Medical), capsules (Hushrooms™), and topical supplements (Hatshe) with proposed national distribution via a strategic agreement with SWAY Energy Corporation. Halo has entered into a letter of intent to acquire Phytocann Holdings, one of Europe's leading wellness CBD consumer packaged goods companies with a portfolio of value and premium brands including Ivory, Harvest Laboratoires, Easy Weed, Kanolia, Herboristerie Alexandra, Buddies and Ghosty Buds.
As an incubator, Halo has successfully acquired and integrated a variety of companies which were subsequently reorganized to create Akanda Corp. (NASDAQ: AKAN), an international medical cannabis and wellness company, of which Halo currently owns approximately 44% of the common shares. Halo has also acquired a range of software development assets, including CannPOS, Cannalift, CannaFeels, and a discrete sublingual dosing technology, Accudab. Halo intends to reorganize these entities (including their intellectual property and patent applications) into a subsidiary called Halo Tek Inc., and to complete a distribution of the shares of Halo Tek Inc. to shareholders on record, at a date to be determined.
For further information regarding Halo, see Halo's disclosure documents on SEDAR at www.sedar.com
This company took me out to the woodshed and whipped me a new one. Not sure where this is going. Two reverse splits and only 10,000,000 shares outstanding. Any attention (positive or negative) given to this stock should make it move dramatically? Do you have any recollection as to what this company is up to? Is there any hope?
Hey Gary...
I had home with the AKAN shares which, Halo had 12.M shares and they were trading at $12.50. That gave them a huge amount of total assets. But, then short sellers stepped in and crushed the shares down to $1.00. From that, I lost a lot of hope and don't know what they could do in order to move forward. I bet the go BK or tap out and get sold... or both. They don't have the cash to float themselves.
Good morning
Hcanf is not trading today. No info on what’s going on with the company and recent threads on Reddit we’re removed.
Did they file today?
geesh!
Maybe they are about to get acquired? Maybe? They have assets. Someone will want those. But, they have no real ability to move forward after AKAN shares were destroyed.
They started trading again. Very strange that you could not buy or sell on my platform, until noon. Almost all of the negative news on Reddit have been removed, which is a good thing. It benefits no one. Sorry for the false alarm.
Halo Collective Names New CEO
Halo Collective Inc. (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) has promoted President Katharyn Field as the company’s CEO.
Field is a proven cannabis industry professional with significant management expertise. She succeeds Kiran Sidhu, who resigned as CEO and as a director on the company's board of directors.
Field takes the helm at Halo with nearly a decade of direct cannabis experience spanning all facets of the business, including strategy, retail, corporate development, business development, HR & organization, legal & regulatory, and investor relations.
Having first entered the cannabis industry in 2014 at Costa Farms where she led the procurement, build-out, and sale of one of five original vertically integrated companies in Florida. Subsequently, Field operated a strategy consulting practice focused on cannabis and also worked at MariMed, Inc. (OTCQX:MRMD) as EVP of corporate development.
“Our focus now is to build on this success, de-emphasizing initiatives in less attractive markets and more effectively harnessing the capabilities we have developed to achieve profitability,” Ryan Kunkel, chair of the board said.
The Toronto-based company has also appointed experienced cannabis professional Cassidy McCord as a director on the board.
This is the second time i have purchased shares within a 2 week period 30,000 at .035 or so. And then another reverse split shredding the value and share count that i had. I am done with these guys for now.
According to TD Waterhouse where I trade these guys have a book value of $53.91. Don't know how accurate that is but it seems like they should be trading a lot higher from that standpoint.
@pauljlaeserhotmail-com It was accurate at one point. Halo has 12.5M shares of Akanda. But, short sellers obliterated AKAN stock. So, Halo no longer has that Book Value. Too bad. I actually thought they could do something with this. Nope. Door got slammed in their faces.
@dhtaylor Hopefully the new ceo can think of something or barring that maybe something happens to stimulate Akanda stock and move it back up.
Halo Labs Completes $6M Series C Growth Financing
Do you have a spare $100? New traders, even with smaller accounts, have seen massive growth in their trading skills following the advice of full-time options trader, Nic Chahine. For a limited time, we're opening up an additional 50 spots to get access to his very own trade setups. Click Here to Learn More (Spots available on a first-come, first serve basis)
BURLINGAME, Calif., July 11, 2022 /PRNewswire/ -- Halo Labs, a leading life science instrumentation company announced it has raised $6M in series C financing. The round was led by Agilent Technologies Inc. and includes participation from existing investors Research Corporation Technologies, Broad Oak Capital Partners, BioAdvance, and members of the Board of Directors and senior management.
This new funding will be used for continued commercialization of Halo Labs' Aura™ platform, increasing manufacturing capacity and developing innovative new products to meet the current and new needs of pharmaceutical researchers.
"For the past two years, Halo Labs has deployed an aggressive growth strategy and has raised the bar for innovation in our market," said Rick Gordon, CEO of Halo Labs. "The fact that we were able to close on a funding round in the current economic environment demonstrates the success of that strategy. Our instruments have been adopted by virtually every major biopharmaceutical company and are now one of the leading tools in cell and gene therapy. With this capital, we will continue our current trajectory and scale our business in some exciting new directions. We are excited to have Agilent as a partner in that journey."
First launched in 2017, Aura from Halo Labs has disrupted pharmaceutical product development by combining multiple stability, quality, and safety assays into one instrument. Now available in six different models, representing tools specific for different therapeutic modalities and development stages, Aura instruments give pharmaceutical scientists access to an unprecedented amount of data in a matter of minutes, allowing for new therapies to move from the lab to the clinic faster and more safely.
Halo Labs in Burlingame, CA is a venture-backed scientific instrumentation and consumable company that commercializes high throughput aggregate, visible and subvisible particle analysis for biopharmaceutical formulation, stability, and product quality control using state-of-the-art custom optics and image processing techniques. Researchers around the globe depend on Halo Labs for unprecedented insights into aggregates and subvisible particles present in their drug products via optical imaging on membranes. For more information, visit www.halolabs.com.
Agilent Technologies Inc.
A-1.06%+ Free Alerts
is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Agilent's Early-Stage Partnerships program (ESP) works with startup companies to provide them with support and industry partnerships while providing strategic long-term value to Agilent. Information about Agilent is available at www.agilent.com.
Hi DH
I know how you feel about Halo, however some of us are and have been stuck in this company for a long.... time. Just thinking, if there are only 2.5 million outstanding shares left after all the splits, would it not be possible for a run up if it starts getting a bid?
Good day DH,
Would it possible for you to explain the advantages/disadvantages of HCANF only having a 2.5 mil. outstanding shares. Outside of an easy rise or fall in share price, due to the min. number of shares how will they raise funds if there are no shares to distribute?
Leave a reply
